Altimmune (ALT) Stock Forecast & Price Target

Compare

3,438 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ALT Analyst Ratings

Moderate Buy

8 Buy

2 Hold

1 Sell

Based on 11 analysts giving stock ratings to

Altimmune

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ALT Stock 12 Month Forecast

Average Price Target

$18.72

▲(425.84% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Altimmune in the last 3 months. The average price target is $18.72 with a high forecast of $28.00 and a low forecast of $3.50. The average price target represents a 425.84% change from the last price of $3.56.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","29":"$29","8.75":"$8.75","15.5":"$15.5","22.25":"$22.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.72,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8.75,15.5,22.25,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.61,5.486153846153846,7.362307692307692,9.23846153846154,11.114615384615385,12.990769230769232,14.866923076923078,16.743076923076924,18.61923076923077,20.495384615384616,22.371538461538464,24.247692307692308,26.123846153846156,{"y":28,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.61,4.772307692307692,5.934615384615384,7.096923076923076,8.259230769230768,9.42153846153846,10.583846153846153,11.746153846153845,12.908461538461538,14.07076923076923,15.233076923076922,16.395384615384614,17.557692307692307,{"y":18.72,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.61,3.6015384615384614,3.593076923076923,3.5846153846153843,3.5761538461538462,3.5676923076923077,3.559230769230769,3.5507692307692307,3.542307692307692,3.5338461538461536,3.5253846153846156,3.516923076923077,3.5084615384615385,{"y":3.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.09,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.7,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.29,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.74,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.85,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.21,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.64,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.17,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.23,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.61,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$28.00

Average Price Target$18.72

Lowest Price Target$3.50

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Dex Genotek

TR | OpenAI - 4o

$4→$3.5

Hold

-1.69%

Downside

Reiterated

08/19/25

AI Generated ArticleAI Generated Article

Patrick Trucchio

H.C. Wainwright

$12

Buy

237.08%

Upside

Reiterated

08/13/25

Altimmune's Pemvidutide Advances Towards Phase 3 Trials with Promising Data and Strategic LeadershipWe assess Altimmune using a discounted cash flow (DCF)- and sum-of-the-parts (SOTP)-based methodology. We assign probabilities of success for pemvidutide (ALT-801) of 75% in MASH and obesity. We employ a 12% discount rate and a terminal multiple of 6.0x. Taken together, these assumptions yield a total firm value of approximately $1.1B and a price target of $12.

Eliana Merle

UBS

$26→$24

Buy

574.16%

Upside

Reiterated

08/13/25

UBS Sticks to Their Buy Rating for Altimmune (ALT)

Mayank Mamtani

B.Riley Financial

$20→$18

Buy

405.62%

Upside

Reiterated

08/13/25

B.Riley Financial Keeps Their Buy Rating on Altimmune (ALT)

Andy Hsieh

William Blair

―

Hold

―

Reiterated

08/12/25

Altimmune's Pemvidutide Faces Uncertainty Amid MASH Market Challenges and Pending DevelopmentsWe expect the company’s current balance sheet to fund operations into 2027.

Corinne Johnson

Goldman Sachs

―

Sell

―

Reiterated

07/18/25

We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.

Jonathan Wolleben

Citizens JMP

$25→$15

Buy

321.35%

Upside

Reiterated

07/10/25

Altimmune price target lowered to $15 from $25 at Citizens JMPAltimmune price target lowered to $15 from $25 at Citizens JMP

Liisa Bayko

Evercore ISI

$25

Buy

602.25%

Upside

Reiterated

06/27/25

Analysts Are Bullish on These Healthcare Stocks: Chemed (CHE), Altimmune (ALT)

Yasmeen Rahimi

Piper Sandler

$25

Buy

602.25%

Upside

Reiterated

06/27/25

Optimistic Outlook for Altimmune's Pemvidutide Despite Phase 2b Setback

Annabel Samimy

Stifel Nicolaus

$18

Buy

405.62%

Upside

Initiated

06/26/25

Altimmune's Pemvi hits MASH goal, shows broad potential, says StifelAltimmune's Pemvi hits MASH goal, shows broad potential, says Stifel

Roger Song

Jefferies

$28

Buy

686.52%

Upside

Reiterated

06/26/25

Altimmune's Pemvidutide: A Promising Candidate for MASH Market with Strong Phase 3 Potential

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Dex Genotek

TR | OpenAI - 4o

$4→$3.5

Hold

-1.69%

Downside

Reiterated

08/19/25

AI Generated ArticleAI Generated Article

Patrick Trucchio

H.C. Wainwright

$12

Buy

237.08%

Upside

Reiterated

08/13/25

Eliana Merle

UBS

$26→$24

Buy

574.16%

Upside

Reiterated

08/13/25

UBS Sticks to Their Buy Rating for Altimmune (ALT)

Mayank Mamtani

B.Riley Financial

$20→$18

Buy

405.62%

Upside

Reiterated

08/13/25

B.Riley Financial Keeps Their Buy Rating on Altimmune (ALT)

Andy Hsieh

William Blair

―

Hold

―

Reiterated

08/12/25

Altimmune's Pemvidutide Faces Uncertainty Amid MASH Market Challenges and Pending DevelopmentsWe expect the company’s current balance sheet to fund operations into 2027.

Corinne Johnson

Goldman Sachs

―

Sell

―

Reiterated

07/18/25

We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.

Jonathan Wolleben

Citizens JMP

$25→$15

Buy

321.35%

Upside

Reiterated

07/10/25

Altimmune price target lowered to $15 from $25 at Citizens JMPAltimmune price target lowered to $15 from $25 at Citizens JMP

Liisa Bayko

Evercore ISI

$25

Buy

602.25%

Upside

Reiterated

06/27/25

Analysts Are Bullish on These Healthcare Stocks: Chemed (CHE), Altimmune (ALT)

Yasmeen Rahimi

Piper Sandler

$25

Buy

602.25%

Upside

Reiterated

06/27/25

Optimistic Outlook for Altimmune's Pemvidutide Despite Phase 2b Setback

Annabel Samimy

Stifel Nicolaus

$18

Buy

405.62%

Upside

Initiated

06/26/25

Altimmune's Pemvi hits MASH goal, shows broad potential, says StifelAltimmune's Pemvi hits MASH goal, shows broad potential, says Stifel

Roger Song

Jefferies

$28

Buy

686.52%

Upside

Reiterated

06/26/25

Altimmune's Pemvidutide: A Promising Candidate for MASH Market with Strong Phase 3 Potential

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Altimmune

1 Month

xxx

Success Rate

16/37 ratings generated profit

Average Return

+15.06%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 43.24% of your transactions generating a profit, with an average return of +15.06% per trade.

3 Months

xxx

Success Rate

16/40 ratings generated profit

Average Return

+29.39%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of +29.39% per trade.

1 Year

Mayank MamtaniB.Riley Financial

Success Rate

14/37 ratings generated profit

Average Return

+2.67%

reiterated a buy rating 7 days ago

Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 37.84% of your transactions generating a profit, with an average return of +2.67% per trade.

2 Years

xxx

Success Rate

14/40 ratings generated profit

Average Return

-20.11%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 35.00% of your transactions generating a profit, with an average return of -20.11% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALT Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ALT has received 12 Buy Ratings, 11 Hold Ratings, and 2 Sell Ratings. ALT average Analyst price target in the past 3 months is 18.72.

Each month's total comprises the sum of three months' worth of ratings.

ALT Financial Forecast

ALT Earnings Forecast

Next quarter’s earnings estimate for ALT is -$0.27 with a range of -$0.32 to -$0.12. The previous quarter’s EPS was -$0.27. ALT beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.19% of the time in the same period. In the last calendar year ALT has Outperformed its overall industry.

ALT Sales Forecast

Next quarter’s sales forecast for ALT is $1.00K with a range of $0.00 to $5.00K. The previous quarter’s sales results were $5.00K. ALT beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.26% of the time in the same period. In the last calendar year ALT has Outperformed its overall industry.

ALT Stock Forecast FAQ

What is ALT’s average 12-month price target, according to analysts?

Based on analyst ratings, Altimmune Inc’s 12-month average price target is 18.72.

What is ALT’s upside potential, based on the analysts’ average price target?

Altimmune Inc has 425.84% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ALT a Buy, Sell or Hold?

Altimmune Inc has a consensus rating of Moderate Buy which is based on 8 buy ratings, 2 hold ratings and 1 sell ratings.

What is Altimmune Inc’s price target?

The average price target for Altimmune Inc is 18.72. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $28.00 ,the lowest forecast is $3.50. The average price target represents 425.84% Increase from the current price of $3.56.

What do analysts say about Altimmune Inc?

Altimmune Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of ALT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Altimmune (ALT) Stock Forecast & Price Target

ALT Analyst Ratings

ALT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Altimmune

ALT Analyst Recommendation Trends

ALT Financial Forecast

ALT Earnings Forecast

ALT Sales Forecast

ALT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts